exist
emerg
viral
cn
infect
major
sourc
human
morbid
mortal
treatment
proven
efficaci
current
limit
predominantli
herpesvirus
human
immunodefici
viru
develop
new
therapi
hamper
lack
appropri
anim
model
system
import
virus
difficulti
conduct
human
clinic
trial
diseas
may
rare
case
arbovir
infect
often
variabl
season
geograph
incid
nonetheless
mani
novel
approach
antivir
therapi
avail
includ
candid
thiazolid
purazinecarboxamid
deriv
potenti
broadspectrum
antivir
efficaci
new
herpesviru
drug
includ
viral
helicaseprimas
terminas
inhibitor
use
antisens
oligonucleotid
strategi
interfer
viral
rna
translat
shown
efficaci
experiment
model
cn
viral
diseas
identifi
specif
molecular
target
within
viral
replic
cycl
led
mani
exist
antivir
undoubtedli
continu
basi
futur
drug
design
promis
new
area
research
involv
therapi
base
enhanc
understand
host
antivir
immun
respons
tolllik
receptor
agonist
drug
inhibit
specif
cytokin
well
interferon
prepar
shown
potenti
therapeut
efficaci
passiv
transfer
virusspecif
cytotox
tlymphocyt
use
human
may
provid
effect
therapi
herpesviru
infect
potenti
progress
multifoc
leukoencephalopathi
human
monoclon
antibodi
direct
specif
viral
protein
develop
sever
case
evalu
human
set
includ
west
nile
viru
hiv
infect
preexposur
prophylaxi
rabi
nation
worldwid
burden
neurolog
infect
continu
grow
new
infect
continu
emerg
rapid
pace
human
explor
everi
remot
corner
planet
use
anim
human
product
treatment
transplant
infect
enter
popul
global
human
travel
help
spread
infect
quickli
recent
emerg
viral
outbreak
includ
caus
hanta
viru
marburg
viru
influenza
strain
sar
coronaviru
enterovir
enceph
west
nile
enceph
viral
infect
frequent
involv
central
nervou
system
better
treatment
becom
avail
treatment
cancer
immun
mediat
diseas
opportunist
infect
also
rise
sever
herpesviru
infect
progress
multifoc
leukoencephalopathi
pml
due
jc
viru
commonli
seen
immun
suppress
individu
addit
mani
patient
undiagnos
meningoenceph
infect
suspect
confirm
one
studi
nearli
one
third
patient
suspect
infect
nervou
system
tertiari
care
facil
remain
undiagnos
current
except
herpesvirus
human
immunodefici
viru
hiv
treatment
proven
efficaci
avail
cn
viral
infect
absenc
treatment
contribut
high
associ
morbid
mortal
lead
larg
health
care
cost
major
socioeconom
consequ
great
need
develop
antivir
therapeut
would
effect
brain
infect
howev
develop
therapeut
infect
central
nervou
system
pose
uniqu
challeng
deliveri
drug
brain
requir
either
use
small
molecul
follow
lipinski
rule
predict
activ
base
pharmacokinet
principl
like
known
activ
drug
requir
direct
deliveri
brain
invas
procedur
lumbar
punctur
reservoir
place
later
ventricl
convect
enhanc
deliveri
howev
suffici
inflamm
associ
infect
may
aid
deliveri
therapeut
agent
site
infect
cerebr
vasculatur
lack
anim
model
cn
infect
eg
jcvinduc
pml
replic
human
diseas
mean
human
studi
may
need
conduct
follow
vitro
efficaci
studi
absenc
preclin
anim
safeti
efficaci
test
enhanc
risk
failur
unexpect
side
effect
exampl
recent
multicent
studi
use
mefloquin
pml
stop
prematur
due
lack
efficaci
human
despit
promis
vitro
studi
possibl
human
rodent
model
could
develop
pathogen
human
virus
process
technic
challeng
potenti
ethic
limit
relat
introduc
human
brain
cell
rodent
brain
conduct
clinic
trial
viral
infect
nervou
system
also
pose
uniqu
challeng
infect
mayb
season
outbreak
may
occur
region
imag
monitor
facil
may
avail
acut
natur
ill
demand
quick
action
set
virus
reactiv
may
alway
pathogen
case
exampl
human
herp
epstein
barr
viru
ebv
rariti
mani
cn
viral
infect
mean
multicent
studi
essenti
even
phase
studi
achiev
target
sampl
size
despit
challeng
sever
multicent
studi
conduct
pml
herp
simplex
viru
enceph
hsve
neurolog
complic
hiv
infect
compani
interest
develop
therapeut
neurovirolog
access
clinic
expertis
section
cn
infect
american
academi
neurolog
wwwaancom
basic
scienc
expertis
intern
societi
neurovirolog
wwwisnvorg
tradit
drug
develop
purview
pharmaceut
compani
limit
interest
rare
diseas
includ
mani
cn
viral
infect
due
limit
ultim
size
potenti
market
recent
pharmaceut
compani
shown
interest
rare
diseas
drug
price
make
profit
high
cost
drug
develop
larg
driven
larg
failur
rate
inabl
predict
efficaci
human
drug
trial
cn
viral
infect
conduct
drug
approv
system
indic
rather
specif
develop
use
cn
possibl
broadspectrum
antivir
develop
penetr
blood
brain
barrier
new
therapeut
would
becom
avail
drug
develop
cn
viral
diseas
one
distinct
advantag
chronic
diseas
avail
measur
viral
load
depend
surrog
marker
diseas
expect
viral
load
decreas
clinic
improv
follow
henc
clinic
trial
could
potenti
conduct
smaller
sampl
size
shorter
period
time
howev
resourc
medicin
chemistri
toxicolog
pharmacodynam
pharmacokinet
studi
limit
academ
institut
unless
aspect
address
challeng
treat
ill
may
continu
forese
futur
follow
section
new
pharmacolog
biolog
immunomodulatori
approach
treatment
cn
viral
diseas
briefli
review
broadspectrum
antivir
tabl
nitazoxanid
ntz
thiazolid
antiinfect
activ
anaerob
bacteria
protozoa
virus
origin
develop
treatment
intestin
protozoan
infect
antivir
properti
ntz
discov
cours
develop
treat
cryptosporidiosi
patient
acquir
immun
defici
syndrom
aid
recent
random
doubl
blind
clinic
trial
demonstr
effect
ntz
treat
rotaviru
noroviru
may
effect
hepat
viru
well
broadspectrum
effect
suggest
drug
deriv
may
candid
test
neurotrop
virus
deliv
across
blood
brain
barrier
seri
pyrazinecarboxamid
deriv
favipiravir
broadspectrum
antivir
drug
target
rna
virus
influenza
viru
arenavirus
bunyavirus
west
nile
viru
yellow
fever
viru
footandmouth
diseas
viru
compound
inhibit
host
dna
rna
synthesi
compound
effect
protect
anim
even
treatment
initi
viru
inocul
importantli
impart
benefici
antivir
effect
without
signific
toxic
host
two
structur
unrel
compound
broadspectrum
activ
virtual
envelop
rna
dna
virus
uniqu
enzym
regulatori
protein
encod
genom
specif
neurotrop
virus
excel
target
specif
antivir
therapi
approach
work
well
exemplifi
drug
target
thymidin
kinas
herp
simplex
viru
hsv
revers
transcriptas
integras
proteas
hiv
understand
step
viral
replic
cycl
allow
similar
approach
neurotrop
virus
exampl
regard
flavivirus
envelop
glycoprotein
sever
enzym
proteas
helicas
methyltransferas
rnadepend
rna
polymeras
potenti
drug
target
similarli
target
viral
proteas
success
drug
boceprevir
telaprivir
develop
hepat
c
viru
becom
clear
current
antiretrovir
therapi
art
abl
elimin
hivassoci
neurocognit
deficit
hand
despit
intensif
antiretrovir
therapi
art
cn
dysfunct
persist
mani
patient
underli
reason
failur
persist
immun
activ
unclear
howev
sever
factor
consid
includ
microbi
transloc
persist
product
earli
viral
product
tat
protein
current
avail
drug
impact
tat
transcript
provir
dna
novel
approach
treatment
hiv
infect
includ
target
host
protein
involv
viral
assembl
matur
howev
drug
target
tat
need
major
shift
hiv
drug
develop
occur
recent
realiz
isol
case
hiv
could
elimin
reservoir
allow
true
cure
diseas
sever
clinic
trial
underway
use
varieti
approach
develop
hiv
resist
lymphocyt
activ
latent
reservoir
immun
system
presenc
art
hope
cytotox
lymphocyt
would
elimin
viral
reservoir
thu
far
approach
fail
produc
cure
concern
rais
activ
hiv
brain
although
acyclovir
remain
wide
use
drug
hsv
recent
year
sever
drug
use
clinic
use
includ
valaciclovir
valganciclovir
famciclovir
foscarnet
drug
clinic
trial
prodrug
cidofovir
helicaseprimas
inhibitor
valin
ester
cf
terminas
inhibitor
letermovir
given
oral
antivir
activ
dna
virus
howev
toxic
cn
deliveri
develop
viral
resist
potenti
limit
factor
gener
use
newer
agent
variat
theme
target
therapi
use
antisens
oligonucleotid
analog
engin
inhibit
translat
viral
protein
specif
bind
rna
sequenc
viral
genom
particular
subtyp
antisens
molecul
one
dna
ribos
ring
replac
morpholin
ring
phosphodiest
linkag
replac
phosphorodiamid
phosphorodiamid
morpholino
oligom
pmo
pmo
success
inhibit
wide
varieti
neurotrop
virus
includ
japanes
enceph
viru
jev
arenavirus
filovirus
cell
cultur
significantli
influenza
alphaviru
sindbi
jev
lymphocyt
choriomening
viru
west
nile
viru
wnv
mice
relat
strategi
use
rna
interfer
smallinterf
rna
sirna
also
proven
success
anim
model
jev
rabi
develop
measl
well
potenti
treat
subacut
scleros
panenceph
caus
persist
measl
infect
success
preclin
studi
led
small
scale
trial
avi
biopharma
sarepta
therapeut
interfer
wnv
mrna
translat
use
pmo
human
trial
relat
studi
suggest
pmo
test
cross
bloodbrainbarri
safe
administ
although
efficaci
data
avail
one
effect
mechan
control
prevent
neurotrop
viral
infect
host
array
innat
acquir
immun
defens
one
illustr
gener
effect
defens
common
caus
viral
enceph
eg
arbovirus
herpesvirus
neuroinvas
diseas
fact
exceedingli
rare
outcom
infect
exampl
million
individu
latent
infect
herpesvirus
yet
like
thousand
case
year
hsve
herpesviru
encephalitid
us
year
similarli
virtual
common
arboviru
infect
eg
wnv
jev
neuroinvas
diseas
occur
infect
data
concern
potenti
role
innat
immun
cellmedi
immun
antibodi
respons
import
cn
viral
infect
briefli
review
along
potenti
opportun
manipul
system
antivir
therapi
rna
dna
produc
viral
replic
recogn
host
pathogen
recognit
receptor
includ
famili
tolllik
receptor
tlr
rigi
like
receptor
rlr
signal
tlr
rlr
act
via
intermediari
protein
eg
interferon
regulatori
factor
induc
new
gene
transcript
activ
antivir
program
best
exemplifi
type
interferon
respons
gene
product
implic
pathophysiolog
viral
infect
exampl
sever
studi
human
anim
link
aspect
wnv
infect
acquisit
symptomat
versu
nonsymptomat
diseas
neuroinvas
diseas
interferonassoci
gene
includ
member
oligoadenyl
synthetas
oa
famili
interferon
regulatori
myxovirusresist
famili
gene
gene
also
link
resist
flaviviru
infect
mice
suscept
develop
wnv
enceph
hors
cytokin
tnfalpha
also
play
role
innat
immun
respons
viral
infect
exampl
wnv
infect
although
suggest
elev
level
tnfalpha
may
increas
risk
develop
west
nile
neuroinvas
diseas
wnnd
impair
endotheli
cell
integr
facilit
viral
entri
across
bloodbrainbarri
mice
lack
treat
neutral
tnfalpha
monoclon
antibodi
show
increas
mortal
wnv
challeng
increas
viral
load
cn
suggest
role
tnfalpha
may
complex
aspect
facilit
neuroinvas
other
facilit
antivir
role
includ
accumul
tcell
macrophag
interestingli
polymorph
tnfalpha
promot
region
associ
alter
transcript
tnfalpha
plasma
level
link
risk
develop
enceph
oppos
milder
febril
ill
follow
jev
infect
exampl
patient
allel
odd
ratio
develop
jev
fever
oppos
enceph
wherea
allel
risk
differ
multipl
studi
mice
indic
tlr
rlr
recogn
wnvassoci
nucleic
acid
gener
viral
replic
subsequ
led
activ
type
interferon
ifn
respons
transcript
respons
mediat
interferon
regulatori
mice
lack
interferon
alpha
beta
receptor
tlr
rlr
show
enhanc
sever
wnv
infect
enhanc
viral
replic
compar
wildtyp
counterpart
case
tlr
defici
least
enhanc
suscept
like
due
failur
leukocyt
macrophag
home
wnvinfect
cell
infiltr
infect
target
organ
similarli
least
part
effect
delet
enhanc
wnv
mortal
spread
link
role
induc
cytokin
turn
facilit
recruit
macrophag
tcell
brain
major
case
hsve
sporad
natur
lack
defin
immunolog
risk
factor
howev
children
inborn
error
signal
defect
result
abnorm
signal
sever
antivir
tlr
includ
eg
defici
suscept
hsve
common
compon
associ
defect
impair
interferon
alphabeta
signal
mani
case
cell
deriv
affect
individu
show
enhanc
hsv
replic
cytopath
phenotyp
rescu
treatment
ifn
alpha
beta
human
genet
data
consist
experiment
studi
show
mice
lack
enhanc
growth
hsv
cn
increas
mortal
intracerebr
viral
challeng
studi
indic
effect
type
ifn
respons
critic
murin
surviv
hsve
murin
studi
also
point
import
tlr
control
hsv
infect
exampl
mice
lack
show
enhanc
mortal
hsv
challeng
import
innat
immun
natur
control
cn
viral
infect
suggest
augment
pathway
could
provid
novel
strategi
antivir
therapi
experiment
evid
avail
support
approach
exampl
mice
treat
combin
acyclovir
ifn
alpha
show
reduct
mortal
hsv
challeng
compar
mice
treat
acyclovir
alon
agonist
tlr
also
studi
murin
model
hsve
agonist
typic
cpg
oligodeoxynucleotid
activ
product
ifnalphabeta
one
studi
mous
model
hsve
intranas
administr
agonist
polyinosin
polycytidyl
acid
intranas
hsv
challeng
reduc
sever
diseas
howev
administr
infect
alreadi
establish
increas
mortal
diseas
sever
similar
experiment
model
agonist
pretreat
increas
surviv
interestingli
antagonist
also
modest
effect
improv
surviv
given
either
follow
viral
challeng
result
suggest
case
cytokin
respons
may
reduc
risk
infect
play
detriment
role
establish
infect
suggest
potenti
complex
target
pathway
antivir
therapi
agonist
ampligen
also
evalu
murin
model
venezuelan
equin
enceph
viru
cn
infect
intranas
intraperiton
administr
ampligen
relat
intranas
venezuelan
equin
enceph
viru
challeng
prevent
neuroinvas
develop
symptomat
diseas
even
ampligen
administ
hr
treat
mice
show
decreas
cn
viral
invas
minim
diseas
anoth
strategi
reduc
product
proinflammatori
cytokin
may
detriment
role
infect
involv
use
tetracyclin
class
antibiot
includ
minocyclin
doxycyclin
agent
may
exert
neuroprotect
effect
reduc
microgli
activ
subsequ
product
proinflammatori
cytokin
benefici
effect
drug
diseas
sever
cn
injuri
report
murin
model
alphaviru
sindbi
flaviviru
jev
reoviru
enceph
macaqu
model
siv
enceph
one
notabl
except
mostli
posit
result
rabi
enceph
therapi
actual
enhanc
diseas
sever
experiment
studi
suggest
manipul
host
innat
immun
respons
might
produc
novel
strategi
treat
cn
viral
infect
one
obviou
approach
tri
treatment
sever
human
neurotrop
viral
infect
involv
direct
administr
interferon
prepar
one
nonrandom
trial
involv
st
loui
enceph
patient
receiv
million
unit
iv
sq
hr
daili
x
day
seem
less
persist
quadriparesi
quadriplegia
respiratori
insuffici
untreat
control
isol
case
report
ifn
therapi
wnv
shown
exampl
appar
benefit
effect
random
placebocontrol
trial
children
vietnam
jev
ifn
million
unitsm
im
x
effect
mortal
incid
sever
sequela
furthermor
ifn
alpha
fail
show
benefit
progress
multifoc
leukoencephalopathi
due
jc
viru
infect
case
hsve
almost
data
avail
one
small
studi
children
acut
focal
enceph
receiv
either
acyclovir
alon
acyclovir
plu
recombin
ifnbeta
appreci
differ
outcom
two
treatment
group
five
licens
tnfalpha
inhibitor
util
treatment
psoriasi
inflammatori
bowel
diseas
rheumatoid
arthriti
adalimumab
etanercept
infliximab
golimumab
certolizumab
data
concern
possibl
util
cn
viral
infect
tlr
agonist
includ
ampligen
human
clinic
trial
set
includ
hiv
infect
eg
chronic
fatigu
syndrom
yet
evalu
cn
infect
potenti
cautionari
note
use
tnfalpha
antagonist
antivir
therapi
come
fact
least
three
case
hsv
enceph
report
patient
treat
infliximab
adalimumab
rheumatolog
disord
includ
psoriat
arthriti
rheumatoid
arthriti
inflammatori
polyarthr
similarli
treatment
tnfalpha
inhibitor
may
increas
risk
herp
zoster
review
german
registri
patient
treat
biolog
found
case
zoster
associ
treatment
tnfalpha
antibodi
adalimumab
infliximab
tnfalpha
antagonist
etanercept
estim
hazard
ratio
correct
epidemiolog
factor
ci
antibodi
nonsignific
hr
ci
etanercept
recent
us
studi
fail
find
increas
risk
herp
zoster
rheumatoid
arthriti
patient
treat
antitnf
therapi
area
remain
unsettl
studi
least
rais
cautionari
possibl
herpesvirus
tnfalpha
may
play
role
control
reactiv
latenc
latent
state
seen
arbovir
infect
potenti
risk
benefit
tnfalpha
inhibit
infect
may
differ
seen
herp
viral
infect
use
tnf
blocker
may
also
increas
risk
reactiv
mycobacteri
infect
may
limit
use
popul
mycobacteri
infect
endem
although
report
pml
patient
receiv
antitnf
therapi
includ
infliximab
etanercept
patient
report
date
diseas
therapi
associ
risk
pml
recent
review
fda
advers
event
report
system
databas
identifi
six
case
patient
rheumat
diseas
conclud
causal
relationship
pml
antitnf
therapi
unlik
cytokin
also
use
simul
immun
system
enhanc
antivir
respons
howev
fail
show
clinic
benefit
two
larg
clinic
trial
supplement
treatment
actual
enhanc
hiv
persist
patient
receiv
antiretrovir
therapi
cytokin
therapi
yet
specif
appli
patient
cn
viral
infect
treatment
tetracyclin
class
antibiot
may
broadspectrum
effect
proinflammatori
cytokin
product
one
clinic
studi
infect
flaviviru
dengu
doxycyclin
treatment
mg
load
mg
x
shown
reduc
serum
level
varieti
proinflammatori
cytokin
tnf
whose
express
link
increasingli
sever
diseas
day
posttreat
compar
control
varieti
studi
suggest
cellular
immun
play
critic
role
control
viral
infect
particular
emphas
critic
role
mediat
tcell
immun
murin
model
wnv
agerel
declin
tcell
respons
may
also
explain
least
agerel
suscept
cn
infect
whether
similar
defect
occur
human
remain
uncertain
mice
lack
tcell
show
decreas
cn
viral
clearanc
increas
mortal
challeng
virul
wnv
strain
although
deplet
may
actual
reduc
sever
diseas
challeng
attenu
wnv
strain
suggest
tcell
may
benefici
effect
acceler
viral
clearanc
potenti
deleteri
effect
via
immunopatholog
import
tcell
viral
clearanc
may
vari
even
virus
famili
exampl
contrast
rel
import
wnv
pathogenesi
tcell
appar
play
much
subsidiari
role
cn
clearanc
anoth
neurotrop
flaviviru
jev
compar
virusspecif
antibodi
failur
wnvspecif
tcell
migrat
cn
even
present
essenti
effect
defici
infect
neuron
cell
result
product
bind
receptor
promot
traffick
virusspecif
tcell
cn
traffick
tcell
cn
also
depend
chemokin
receptor
mice
lack
increas
mortal
higher
wnv
viral
titer
brain
pauciti
infiltr
inflammatori
cell
defici
may
also
exacerb
experiment
hsve
approxim
us
caucasian
popul
homozyg
delet
result
complet
loss
function
presenc
homozygos
increas
suscept
wnv
infect
increas
risk
sever
wnv
diseas
approxim
also
well
known
coreceptor
hiv
infect
contrast
individu
mutat
milder
form
diseas
slower
progress
tradit
vaccin
use
mean
boost
immun
respons
viral
pathogen
approach
success
vzv
prevent
zoster
similar
approach
consid
jc
viru
howev
approach
may
limit
patient
signific
immun
suppress
henc
approach
consid
passiv
transfer
virusspecif
cytotox
cell
ctl
protect
diseas
studi
suggest
possibl
transfer
virusspecif
immun
cell
may
use
treatment
human
viral
cn
infect
proof
principl
human
cn
diseas
come
treatment
patient
pml
follow
hematopoiet
stem
cell
transplant
immunosuppress
graft
versu
host
diseas
peripher
blood
mononuclear
cell
pbmc
obtain
stem
cell
donor
jc
viru
antigenspecif
ctl
gener
vitro
stimul
cell
peptid
deriv
jc
viru
one
month
patient
receiv
two
infus
develop
measur
ctl
activ
viral
protein
detect
preinfus
show
remark
sign
clinic
ambul
motor
function
cognit
mri
improv
clear
viru
csf
patient
also
receiv
antivir
therapi
alter
immunosuppress
therapi
possibl
unequivoc
attribut
respons
immunotherapi
nonetheless
case
show
potenti
feasibl
gener
infus
virusspecif
ctl
impart
measur
antivir
ctl
activ
recipi
done
safe
number
studi
passiv
transfer
donorderiv
cytomegaloviru
cmv
epstein
barr
viru
ebv
specif
ctl
report
techniqu
matur
effort
focus
develop
rapid
cultur
vitro
stimul
viral
peptid
follow
select
purifi
ifngamma
secret
cell
transfer
back
host
accomplish
less
hr
see
transfer
typic
result
develop
measur
viralspecif
ctl
activ
recipi
often
absent
pretransf
cell
transfer
use
success
patient
diseas
refractori
antivir
therapi
model
prophylaxi
one
studi
involv
patient
two
cmv
enceph
respond
clinic
clearanc
viru
blood
csf
immunotherapi
virusspecif
ctl
donor
pbmc
also
isol
bind
tcell
receptor
specif
construct
multim
contain
target
interest
eg
cmv
ebv
ebna
peptid
coupl
appropri
mhc
hla
perhap
beststudi
compon
host
defens
viral
infect
gener
virusspecif
antibodi
respons
advent
monoclon
antibodi
mab
technolog
becam
possibl
map
protect
epitop
specif
viral
protein
review
shown
virus
passiv
transfer
mab
direct
protein
could
clear
viru
viral
nucleic
acid
cn
neuron
even
mice
defici
cellular
immun
clearanc
could
occur
infect
cn
establish
human
form
antibodi
develop
similar
protect
capac
experiment
model
enceph
involv
arbovirus
venezuelan
equin
enceph
jev
wnv
well
postexposur
prophylaxi
pep
rabi
human
monoclon
antibodi
also
test
anim
model
neurotrop
virus
includ
enteroviru
model
infect
influenza
virus
includ
pandem
studi
use
human
mab
treatment
herpesviru
infect
limit
although
one
report
use
human
antihsv
mab
mous
model
hsv
ocular
diseas
antibodytr
anim
significantli
reduc
ocular
diseas
human
monoclon
antibodi
direct
epitop
wnv
envelop
glycoprotein
protect
mous
hamster
model
wnv
enceph
test
safeti
human
antibodi
administ
normal
volunt
dose
mgkg
intraven
infus
well
toler
pharmacokinet
studi
indic
halflif
level
achiev
substanti
exceed
requir
protect
hamster
model
howev
enrol
patient
acut
enceph
clinic
trial
challeng
anoth
promis
area
use
human
monoclon
antibodi
pep
rabi
viru
infect
estim
million
peopl
worldwid
receiv
rabi
pep
everi
year
minimum
rabi
death
occur
current
regimen
reli
use
either
human
equin
rabi
immun
globulin
coadminist
rabi
vaccin
phase
trial
indic
cocktail
human
antirabi
viru
monoclon
antibodi
manufactur
crucel
holland
bv
administ
intramuscularli
safe
phase
human
trial
interfer
develop
subsequ
vaccineinduc
rabi
viru
neutral
antibodi
two
phase
ii
trial
complet
children
adolesc
philippin
adult
us
follow
third
trial
adult
india
complet
late
data
avail
suggest
human
mab
viabl
altern
polyclon
antirabi
immunoglobulin
pep
new
technolog
approach
may
enhanc
util
human
monoclon
antibodi
approach
cn
viral
infect
almost
trial
human
monoclon
antibodi
util
passiv
transfer
techniqu
antibodi
directli
administ
either
intraven
eg
wnv
intramuscularli
rabi
novel
strategi
refer
vector
immunoprophylaxi
vip
util
gene
transfer
express
high
level
antibodi
prolong
period
human
mab
transfer
convent
passiv
method
protect
mice
human
immun
system
hiv
challeng
human
neutral
antihiv
ab
also
protect
express
singl
intramuscular
inject
mice
use
adeno
associ
vector
aav
system
antibodi
detect
within
week
inject
peak
week
persist
week
type
model
may
promis
approach
avoid
repeat
administr
antibodi
situat
chronic
diseas
continu
risk
exposur
treatment
must
ideal
maintain
period
exceed
halflif
individu
antibodi
administr
note
typic
target
human
antivir
antibodi
specif
viral
protein
use
cocktail
pool
sever
antibodi
may
enhanc
efficaci
reduc
likelihood
select
viral
escap
mutant
anoth
strategi
use
antibodi
target
key
host
cell
compon
involv
viral
bind
entri
rather
viral
protein
per
se
strategi
success
util
hiv
infect
two
differ
human
mab
pro
direct
domain
aminotermin
extracellular
loop
hiv
receptor
shown
safe
well
toler
reduc
plasma
hiv
viral
load
phase
iii
trial
phase
trial
also
shown
similar
safeti
efficaci
human
monoclon
antibodi
ibalizumab
direct
new
therapi
viral
cn
infect
develop
base
understand
target
specif
step
viru
replic
cycl
util
knowledg
gain
increasingli
sophist
understand
host
antivir
immun
respons
includ
innat
humor
cellmedi
immun
host
potenti
novel
approach
cn
antivir
therapi
avail
experiment
preclin
level
rariti
mani
cn
infect
unpredict
especi
vectorborn
diseas
pose
formid
challeng
design
clinic
trial
equal
daunt
challeng
establish
econom
viabl
pathway
new
drug
develop
nonetheless
econom
public
health
burden
exist
ever
emerg
cn
viral
threat
make
progress
identifi
specif
broadspectrum
antivir
therapi
imper
